Skip to main content
. 2022 Jun 30;6:e2100531. doi: 10.1200/PO.21.00531

FIG 3.

FIG 3.

Treatment history of two patients with metastatic castration-resistant prostate cancer with co-occurring MSI-H and BRCAm. (A) Patient 1 was MSI-H with a BRCA1 mutation, and (B) patient 2 was MSI-H with a BRCA2 mutation. CN, copy number; gLOH, genome-wide loss of heterozygosity; LOH, loss of heterozygosity; MSI, microsatellite instability; MSI-H, microsatellite instability high; PSA, prostate-specific antigen; TMB, tumor mutational burden.